EZH2 and small cell lung carcinoma: Multiple studies have shown that inhibiting EZH2 does not reverse the NE phenotype of T-SCLC [48,55], suggesting it does not have a role in the maintenance of T-SCLC, although it is possible that it could have a role during early steps of transformation.